{"id":1973,"date":"2026-09-28T00:00:00","date_gmt":"2026-09-28T00:00:00","guid":{"rendered":"https:\/\/chatscopeai.com\/news\/european-union-council-backs-pharma-package-setting-nine-year\/"},"modified":"2026-10-01T08:11:03","modified_gmt":"2026-10-01T08:11:03","slug":"european-union-council-backs-pharma-package-setting-nine-year","status":"publish","type":"post","link":"https:\/\/chatscopeai.com\/news\/european-union-council-backs-pharma-package-setting-nine-year\/","title":{"rendered":"European Union Council Backs Pharma Package Setting Nine-Year Medicine Protection"},"content":{"rendered":"\n<p class=\"wp-block-paragraph hsn-lede\">European Union governments adopted the Council position on the pharma package on 28 September 2026, setting nine years of baseline protection for new medicines, with a Parliament vote indicatively due on 23 November 2026.<\/p>\n<p class=\"wp-block-paragraph\">The Council of the European Union adopted its position on the EU &quot;pharma package&quot; on Sept. 28, 2026, approving a new regulation and directive that rewrite the rules for how drug makers develop, authorise and supply human medicines across the bloc<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\" id=\"hsn-cite-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">In short, the Council has signed off on the biggest change to EU medicines law in 20 years, but the European Parliament must still vote before it becomes law. Once in force, drug companies face shorter default protection from generic competition, new duties to supply every member state and prevent shortages, and new rewards for antibiotics.<\/p>\n<p class=\"wp-block-paragraph\">The Council&#8217;s vote completes its first-reading stage. A European Commission communication dated Sept. 29, 2026, says the Council position &quot;fully reflects&quot; the political deal the Council and Parliament struck on Dec. 11, 2025, and that the Commission can accept it<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Parliament&#8217;s public health committee approved the agreed text on March 18, 2026, and the plenary vote is pencilled in for Nov. 23, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\" id=\"hsn-cite-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">What does the EU pharma package replace?<\/h2>\n<p class=\"wp-block-paragraph\">The package is made up of two laws: a directive on a Union code for human medicines, and a regulation on EU authorisation procedures and the European Medicines Agency (EMA)<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\" id=\"hsn-cite-3\">3<\/a><\/sup>. Together they replace four existing acts: Directive 2001\/83\/EC, Regulation (EC) No 726\/2004, the Paediatric Regulation and the Orphan Regulation for rare-disease medicines<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The new law also makes targeted changes to the rules on advanced therapies, the Clinical Trials Regulation and EMA&#8217;s extended mandate<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\" id=\"hsn-cite-4\">4<\/a><\/sup>. The Commission first proposed the reform on April 26, 2023<sup class=\"hsn-cite\"><a href=\"#hsn-ref-5\" id=\"hsn-cite-5\">5<\/a><\/sup>. The Commission&#8217;s stated aims include faster access to medicines, more innovation, fewer shortages and less paperwork for companies and regulators<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">How long will new medicines be protected from generics?<\/h2>\n<p class=\"wp-block-paragraph\">Two kinds of protection keep cheaper copies off the market. Data protection stops competitors relying on the original maker&#8217;s trial data. Market protection stops generic and biosimilar versions from being sold<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">Under the agreed text, a new medicine gets a <strong>nine-year baseline protection<\/strong>: eight years of data protection and one year of market protection<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Companies can earn extra time in several ways:<\/p>\n<ul>\n<li>one more year of market protection for a medicine that meets an unmet medical need;<\/li>\n<li>or one more year for a new active substance tested against existing treatments in clinical trials, combined with trials in several EU countries or an early EU application;<\/li>\n<li>one year for a new use that brings significant clinical benefit.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">The first two routes are alternatives, granted at the time of first approval<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Total protection is capped at 11 years<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">How do the rules change for rare-disease medicines?<\/h2>\n<p class=\"wp-block-paragraph\">Medicines for rare diseases, known as orphan medicines, get nine years of market exclusivity, a period during which similar products cannot be approved<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. &quot;Breakthrough&quot; orphans earn two more years. These are medicines for conditions with no other treatment that clinically reduce illness or death among patients<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v2\" data-at=\"how-do-the-rules-change-for-rare-disease-medicines\">\n  <div class=\"hsn-fig__table\">\n    <h4>Protection periods under the pharma package<\/h4>\n    <div class=\"pcrstb-wrap\"><table>\n      <thead>\n        <tr><th>Question<\/th><th>New medicines<\/th><th>Orphan medicines<\/th><\/tr>\n      <\/thead>\n      <tbody>\n        <tr><th>Baseline<\/th><td>8 years data plus 1 year market protection<\/td><td>9 years market exclusivity<\/td><\/tr>\n        <tr><th>Main extra time<\/th><td>1 year for unmet need or comparative trials<\/td><td>2 years for breakthrough orphans<\/td><\/tr>\n        <tr><th>Maximum<\/th><td>11 years<\/td><td>13 years<\/td><\/tr>\n      <\/tbody>\n    <\/table><\/div>\n  <\/div>\n<\/figure>\n<p class=\"wp-block-paragraph\">A further year is available, up to twice, for new uses in a different rare condition. All the extra years together cap orphan exclusivity at <strong>a maximum of 13 years<\/strong><sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">What do companies get for new antibiotics?<\/h2>\n<p class=\"wp-block-paragraph\">The package creates a transferable exclusivity voucher, a reward for developing a new &quot;priority antimicrobial,&quot; a medicine needed to fight drug-resistant infections<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The voucher grants one extra year of data protection. The company can apply it to the antimicrobial itself or, under conditions, transfer it to another medicine<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">Two limits apply. The voucher cannot be used on a product with annual gross sales over <strong>EUR 490 million<\/strong> in any of its first four years after approval<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. And the company must file its EU application <strong>within 180 days<\/strong> of its first application outside the EU<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">Member states may also buy antimicrobials jointly under a voluntary &quot;subscription model,&quot; which pays developers steady revenue<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. All antimicrobials will need a prescription, and patient leaflets must carry specific information<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">What must drug makers do on supply and shortages?<\/h2>\n<p class=\"wp-block-paragraph\">Member states may require the holder of a marketing authorisation, the company licensed to sell a medicine, to take specific steps to supply it<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The aim is enough continuous supply to meet patients&#8217; needs in every member state concerned<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">Companies must notify supply disruptions six months ahead, and national regulators will monitor expected and actual shortages<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. <strong>Shortage prevention plans<\/strong> become mandatory six months after the regulation enters into force. They cover prescription medicines and certain medicines the Commission identifies<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">Generic and biosimilar makers gain from a wider Bolar exemption, the rule that lets them test copies before the original patent expires<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. They may now also seek pricing, reimbursement and health technology assessment decisions, and join public tenders, while the patent still runs. This lets generics launch on day one after protection ends<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">What else changes at EMA and for companies?<\/h2>\n<p class=\"wp-block-paragraph\">EMA&#8217;s scientific committees will be simplified and reduced in number. The standard assessment time for a medicine falls from 210 days to 180 days<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v2\" data-at=\"what-else-changes-at-ema-and-for-companies\">\n    <div class=\"hsn-fig__chart\">\n    <h4>Standard EMA assessment time, days<\/h4>\n    <div class=\"hsn-fig__bar\" data-series=\"1\">\n      <span class=\"hsn-fig__lab\">Current<\/span>\n      <span class=\"hsn-fig__bartrack\"><span class=\"hsn-fig__barfill\" data-v=\"100\"><\/span><\/span>\n      <span class=\"hsn-fig__num\">210 days<\/span>\n    <\/div>\n    <div class=\"hsn-fig__bar\" data-series=\"2\">\n      <span class=\"hsn-fig__lab\">Under the package<\/span>\n      <span class=\"hsn-fig__bartrack\"><span class=\"hsn-fig__barfill\" data-v=\"85\"><\/span><\/span>\n      <span class=\"hsn-fig__num\">180 days<\/span>\n    <\/div>\n  <\/div><\/figure>\n<p class=\"wp-block-paragraph\">Companies must publicly declare any direct financial support from public bodies, charities or non-profit funds<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Environmental risk assessments for antimicrobials must now cover manufacturing<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Rules on abortion drugs and contraceptives stay unchanged, and restricting them remains a national matter<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">When will the EU medicines rules apply?<\/h2>\n<p class=\"wp-block-paragraph\">Member states have <strong>24 months to transpose<\/strong> the directive into national law, and the regulation applies on the same timetable<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. EMA describes the period up to 2028 as a transition, during which the Commission, EMA and national regulators will issue implementation guidance<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>.<\/p>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v2\" data-at=\"when-will-the-eu-medicines-rules-apply\">\n  <div class=\"hsn-fig__axis\">\n    <h4>Road to the new medicines law<\/h4>\n    <div class=\"hsn-fig__ev\">\n      <span class=\"hsn-fig__evdate\">11 Dec 2025<\/span>\n      <span class=\"hsn-fig__evlab\">Council and Parliament deal<\/span>\n    <\/div>\n    <div class=\"hsn-fig__ev\">\n      <span class=\"hsn-fig__evdate\">28 Sep 2026<\/span>\n      <span class=\"hsn-fig__evlab\">Council adopts position<\/span>\n    <\/div>\n    <div class=\"hsn-fig__ev\">\n      <span class=\"hsn-fig__evdate\">23 Nov 2026<\/span>\n      <span class=\"hsn-fig__evlab\">Indicative Parliament vote<\/span>\n    <\/div>\n  <\/div>\n<\/figure>\n<p class=\"wp-block-paragraph\">Some parts start earlier. The antibiotic voucher, regulatory sandboxes and subscription model guidelines apply from entry into force<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Member states may apply the access rules 12 months after the directive enters into force, and electronic product information applies six months before the general date<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The next step is Parliament&#8217;s plenary vote, indicatively set for Nov. 23, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading hsn-refs-title\">Sources<\/h2>\n<ol class=\"hsn-refs\">\n<li id=\"hsn-ref-1\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-1\" aria-label=\"Back to reference 1 in the text\">\u21a9<\/a> <a href=\"https:\/\/eur-lex.europa.eu\/smartapi\/cgi\/sga_doc?smartapi!celexplus!prod!DocNumber&amp;lg=EN&amp;type_doc=COMfinal&amp;an_doc=2026&amp;nu_doc=0527\" rel=\"noopener\" target=\"_blank\">EUR-Lex &#8211; 52026PC0527 &#8211; EN &#8211; EUR-Lex<\/a> <span class=\"hsn-refs__url\">https:\/\/eur-lex.europa.eu\/smartapi\/cgi\/sga_doc?smartapi!celexplus!prod!DocNumber&amp;lg=EN&amp;type_doc=COMfinal&amp;an_doc=2026&amp;nu_doc=0527<\/span><\/li>\n<li id=\"hsn-ref-2\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-2\" aria-label=\"Back to reference 2 in the text\">\u21a9<\/a> <a href=\"https:\/\/oeil.secure.europarl.europa.eu\/oeil\/en\/procedure-file?reference=2023\/0131(COD)\" rel=\"noopener\" target=\"_blank\">Procedure File: 2023\/0131(COD) | Legislative Observatory | European Parliament<\/a> <span class=\"hsn-refs__url\">https:\/\/oeil.secure.europarl.europa.eu\/oeil\/en\/procedure-file?reference=2023\/0131(COD)<\/span><\/li>\n<li id=\"hsn-ref-3\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-3\" aria-label=\"Back to reference 3 in the text\">\u21a9<\/a> <a href=\"https:\/\/www.europarl.europa.eu\/legislative-train\/spotlight-JD%2023-24\/file-revision-of-the-pharmaceutical-legislation\" rel=\"noopener\" target=\"_blank\">Carriages preview | Legislative Train Schedule<\/a> <span class=\"hsn-refs__url\">https:\/\/www.europarl.europa.eu\/legislative-train\/spotlight-JD%2023-24\/file-revision-of-the-pharmaceutical-legislation<\/span><\/li>\n<li id=\"hsn-ref-4\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-4\" aria-label=\"Back to reference 4 in the text\">\u21a9<\/a> <a href=\"https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/reform-eu-pharmaceutical-legislation\" rel=\"noopener\" target=\"_blank\">Reform of the EU pharmaceutical legislation | European Medicines Agency (EMA)<\/a> <span class=\"hsn-refs__url\">https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/reform-eu-pharmaceutical-legislation<\/span><\/li>\n<li id=\"hsn-ref-5\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-5\" aria-label=\"Back to reference 5 in the text\">\u21a9<\/a> <a href=\"https:\/\/health.ec.europa.eu\/medicinal-products\/reform-eu-pharmaceutical-legislation_en\" rel=\"noopener\" target=\"_blank\">Reform of EU pharmaceutical legislation &#8211; Public Health<\/a> <span class=\"hsn-refs__url\">https:\/\/health.ec.europa.eu\/medicinal-products\/reform-eu-pharmaceutical-legislation_en<\/span><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>European Union governments adopted the Council position on the pharma package on 28 September 2026, setting nine years of baseline protection for new\u2026<\/p>\n","protected":false},"author":1,"featured_media":1972,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_regnews_id":"35593","_hsn_citations":"[{\"n\":1,\"url\":\"https:\/\/eur-lex.europa.eu\/smartapi\/cgi\/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2026&nu_doc=0527\",\"label\":\"EUR-Lex - 52026PC0527 - EN - EUR-Lex\"},{\"n\":2,\"url\":\"https:\/\/oeil.secure.europarl.europa.eu\/oeil\/en\/procedure-file?reference=2023\/0131(COD)\",\"label\":\"Procedure File: 2023\/0131(COD) | Legislative Observatory | European Parliament\"},{\"n\":3,\"url\":\"https:\/\/www.europarl.europa.eu\/legislative-train\/spotlight-JD%2023-24\/file-revision-of-the-pharmaceutical-legislation\",\"label\":\"Carriages preview | Legislative Train Schedule\"},{\"n\":4,\"url\":\"https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/reform-eu-pharmaceutical-legislation\",\"label\":\"Reform of the EU pharmaceutical legislation | European Medicines Agency (EMA)\"},{\"n\":5,\"url\":\"https:\/\/health.ec.europa.eu\/medicinal-products\/reform-eu-pharmaceutical-legislation_en\",\"label\":\"Reform of EU pharmaceutical legislation - Public Health\"}]","_hsn_no_sources":"","_hsn_content_hash":"76142415925ac300a6cb364fe2c52d9ce602e316:0a6a6a288155d771e2bc1634d3e68dd30e127ac8","_yoast_wpseo_focuskw":"pharmaceutical","footnotes":""},"categories":[53,40],"tags":[45],"class_list":["post-1973","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europe","category-pharma-medical","tag-european-union"],"_links":{"self":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/1973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/comments?post=1973"}],"version-history":[{"count":1,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/1973\/revisions"}],"predecessor-version":[{"id":1975,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/1973\/revisions\/1975"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/media\/1972"}],"wp:attachment":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/media?parent=1973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/categories?post=1973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/tags?post=1973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}